Evaluation of serum vascular cell adhesion marker-1 in β- thalassemia major patients

Abstract: BACKGROUND: Defects in the production of one or more hemoglobin chains result in a set of hereditary hematologic illnesses known as thalassemias. Alpha and β-thalassemia are the two primary thalassemia classifications. The pathophysiology of β-thalassemia is significantly influenced by endothelial activation markers, such as vascular cell adhesion molecule 1 (VCAM-1), which have been found to be higher in both transfusion-dependent and nontransfusion-dependent thalassemia patients. These markers have been suggested for the follow-up of vascular disease in this patient group. OBJECTIVES: The aim of this study was to evaluate the level of soluble VCAM-1 in β-thalassemia major patients and to correlate its level with the clinical parameters. PATIENTS, MATERIALS AND METHODS: This case–control study was enrolled on 40 patients with β-thalassemia major. They were collected from Thalassemia Center of Babylon Maternity and Pediatrics Teaching Hospital, from December 28, 2022, to March 30, 2023. Twenty of them were splenectomized, others were not. Another 40 apparently healthy individuals with no family history of thalassemia or other hemoglobinopathy were enrolled in this study as controls. The samples were collected to assay the human VCAM-1 using enzyme-linked immunosorbent assay based on the biotin double antibody sandwich technology. RESULTS: Among 80 subjects, age and body mass index were similar across groups. There are differences in complete blood count (CBC) parameters between thalassemic and control groups. Thalassemic patients displayed notably higher levels of VCAM-1 and ferritin compared to controls and in splenectomized patients than nonsplenectomized patients. There is a high significant correlation exists between VCAM-1 and ferritin, VCAM-1 and various CBC parameters. CONCLUSIONS: There are higher levels of VCAM-1 in β-thalassemia major patients compared to the control and in splenectomized compared to non-splenectomized patients which usually associated with disease complications, furthermore it reflect endothelial activation and dysfunction.

Authors

Institutions

Publication Details

Journal
Iraqi Journal of Hematology
Published
2025-01-01
DOI
https://doi.org/10.4103/ijh.ijh_60_24
Citations
1
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of serum vascular cell adhesion marker-1 in β- thalassemia major patients

R Najm, Subh Salim Al-Mudallal, Nuha Abd Ali Al-Sarai
1 citations
Iraqi Journal of Hematology
Hemoglobinopathies and Related Disorders
1.63
article

Evaluation of serum vascular cell adhesion marker-1 in β- thalassemia major patients

R Najm, Subh Salim Al-Mudallal, Nuha Abd Ali Al-Sarai
article en
1 citations

Abstract

Abstract: BACKGROUND: Defects in the production of one or more hemoglobin chains result in a set of hereditary hematologic illnesses known as thalassemias. Alpha and β-thalassemia are the two primary thalassemia classifications. The pathophysiology of β-thalassemia is significantly influenced by endothelial activation markers, such as vascular cell adhesion molecule 1 (VCAM-1), which have been found to be higher in both transfusion-dependent and nontransfusion-dependent thalassemia patients. These markers have been suggested for the follow-up of vascular disease in this patient group. OBJECTIVES: The aim of this study was to evaluate the level of soluble VCAM-1 in β-thalassemia major patients and to correlate its level with the clinical parameters. PATIENTS, MATERIALS AND METHODS: This case–control study was enrolled on 40 patients with β-thalassemia major. They were collected from Thalassemia Center of Babylon Maternity and Pediatrics Teaching Hospital, from December 28, 2022, to March 30, 2023. Twenty of them were splenectomized, others were not. Another 40 apparently healthy individuals with no family history of thalassemia or other hemoglobinopathy were enrolled in this study as controls. The samples were collected to assay the human VCAM-1 using enzyme-linked immunosorbent assay based on the biotin double antibody sandwich technology. RESULTS: Among 80 subjects, age and body mass index were similar across groups. There are differences in complete blood count (CBC) parameters between thalassemic and control groups. Thalassemic patients displayed notably higher levels of VCAM-1 and ferritin compared to controls and in splenectomized patients than nonsplenectomized patients. There is a high significant correlation exists between VCAM-1 and ferritin, VCAM-1 and various CBC parameters. CONCLUSIONS: There are higher levels of VCAM-1 in β-thalassemia major patients compared to the control and in splenectomized compared to non-splenectomized patients which usually associated with disease complications, furthermore it reflect endothelial activation and dysfunction.

Iraqi Journal of HematologyVol. 14(1)
Baghdad Medical City (IQ)
Good health and well-being
Openalex Percentile: Top 21%
Hemoglobinopathies and Related Disorders
1.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.